Orchestra BioMed Holdings, Inc. (OBIO) stock forecast and price target
Price $7.25 · data as of November 13, 2026
12-month price target
Average target$12.83
Upside / downside+77.0%
Analysts6
ConsensusStrong buy
Low $10.00Average $12.83High $20.00
Gold marker: average target · white marker: today’s price ($7.25)
Analyst ratings
Strong buy 1Buy 5Hold 0Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-1.33 | −20.1% | $393170 |
| Next fiscal year ends December 31, 2027 | $-1.27 | +4.8% | $600140 |
| Next quarter ends December 31, 2026 | $-0.33 | −226.9% | $96670 |
| Quarter after ends December 31, 2026 | $-0.31 | −219.2% | $102200 |
Consensus of the analysts covering Orchestra BioMed, updated daily. In the last 30 days 2 estimates were raised and 1 lowered.
Frequently asked questions
What is the Orchestra BioMed stock price target?
The average 12-month target from 6 analysts is $12.83, 77.0% above the current price of $7.25 Targets range from $10.00 to $20.00.
Is Orchestra BioMed a buy according to analysts?
The consensus rating is “Strong buy” (1 strong buy, 5 buy). Ratings are opinions, not guarantees; this is not investment advice.
How much is Orchestra BioMed expected to earn?
Analysts expect EPS of $-1.33 for the fiscal year ending December 31, 2026 and $-1.27 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.